(MedPage Today) — GLP-1 receptor agonist use was tied to a lower risk of recurrent major adverse limb events (MALEs) in people with diabetes compared with another drug class, a retrospective Taiwanese study showed.
Among 17,288 patients, new…
Source link : https://www.medpagetoday.com/endocrinology/diabetes/119654
Author :
Publish date : 2026-01-29 22:07:00
Copyright for syndicated content belongs to the linked Source.
